-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Yuandong Biopharmaceuticals released its 2021 semi-annual report.
With the continuous growth of sales of its main products and the contribution of new increments from centralized procurement and bidding, the company achieved a net profit of 117 million yuan, a year-on-year increase of 36.
32%
.
The company's follow-up performance is expected to continue to receive "assistances" in centralized procurement: 3 varieties won the bid for the fifth batch of centralized procurement, and two "barefoot" varieties are expected to be included in the sixth batch of centralized procurement
.
The company continues to accelerate its innovation and transformation.
Among the more than 10 class 1 innovative drugs under development, the small molecule new drugs yougliptin tablets and CX3002 tablets will start phase III and phase II clinical trials respectively; the new biological class 1 drug EP-9001A injection will soon Carry out I clinical trials
.
Net profit soared 36.
32% ! Yuandong
Biotech’s net profit of “assisted” by the new bid-winning products (unit: 100 million yuan) Recently, Yuandong Biotech, a pharmaceutical company listed on the Science and Technology Innovation Board, released its 2021 semi-annual report.
The company achieved operating income of 499 million yuan in the first half of the year, a year-on-year increase of 14.
65 %; Achieved a net profit of 117 million yuan, a year-on-year increase of 36.
32%
.
For revenue, net profit double reason for the growth, bio-Yuan Dong, said the company's main products are chemicals sector ibandronate injection and other sales continued to grow, etoricoxib film the third installment of the successful National Drug centralized purchasing contribution Due to the new increment
.
It is worth noting that this is not the first time that Yuandong Biotech's net profit has benefited from the growth of collectively sourced varieties
.
On January 17, 2020, the second batch of centralized procurement was opened.
Yuandong Biological's bisoprolol fumarate tablets won the first place.
The increase in sales has become one of the factors for the company's 2020 net profit growth of 64.
04%
.
The follow-up performance of Yuandong Biology is also expected to continue to receive "assistances" from collectively sourced varieties
.
In the fifth batch of centralized procurement, which opened on June 23, the three shortlisted varieties of Yuandong Biotechnology won the first bid.
Among them, glycopyrrolate injection and dabigatran etexilate capsules were released in November 2020.
It was approved for production in April and April 2021, and the market is waiting to be developed; although Fasudil Hydrochloride Injection has been on the market for many years, its market share is relatively low
.
Winning the bids for the three varieties of national procurement will help expand sales and quickly open up the domestic market
.
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
15 products have been over-evaluated, and 12 new products have
passed/deemedly passed the consistency evaluation.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Yuandong Bio has 15 varieties (28 product regulations) passed/deemed to have passed the consistency evaluation, of which 4 varieties have been evaluated for the first time, and ibandronate sodium injection has temporarily been evaluated exclusively
.
It is worth noting that Paricalcitol injection, propofol tenofovir fumarate tablets, coffee citrate/phenanthrene/injection, memantine hydrochloride sustained-release capsules, ibandronate sodium injection, etc.
Five varieties have not yet been included in the collection
.
The sixth batch of centralized procurement is expected to be launched at the end of this year.
Three types of over-evaluated companies including Memantine Hydrochloride Sustained Release Capsules, Citrate Coffee/Ephine/Yin Injection, Propofol Fumarate Tenofovir Tablets, etc.
have reached 4 Home, 6, and 12 are expected to be included in the next batch of centralized procurement
.
Among them, Yuandong Bio's memantine hydrochloride sustained-release capsules and propofol tenofovir fumarate tablets have just been approved soon.
If the bid is won, it is expected to bring new increments
.
According to data from Mi Nei.
com, there are currently 11 new registered classification varieties (15 acceptance numbers) currently under review by Yuandong Biotechnology, which will be deemed to have passed the consistency evaluation after approval for production
.
Among them, three varieties of bripiprazole tablets, sugammadex sodium injection, and ibuprofen tromethamine injection have not been approved for generic drugs in the domestic market, and ibuprofen tromethamine injection has been approved by Yuanyuan Dong Biotech’s exclusive report for production, is expected to win the first imitation
.
Yuandong Biologics is reviewing the new registration classification of generic drugs.
Source: Meinenet MED2.
0 China Drug Evaluation Database 9 major Class 1 new drugs are eye-
catching , aiming at the field of narcotic and analgesia Yuandong
Biologics R&D expenses (unit: 100 million yuan) In recent years, Yuandong Biology continues to maintain a high R&D investment, has a rich layout in research pipelines, and builds a benign product iteration capability to ensure sustainable development
.
In the first half of 2021, Yuandong Biotechnology's research and development expenses were RMB 94,290,500, a year-on-year increase of 43.
16%
.
Currently, Yuandong Biology has more than 50 research projects, and innovative drug projects account for 20%.
It focuses on key areas to coordinate the deployment of small molecule entities, biological drugs and high-end generic drug product groups, covering diabetes, cardiovascular, anesthesia, analgesia, and anti-inflammatory drugs.
Oncology field
.
Among the more than 10 Class 1 innovative drugs being developed by Yuandong Biotechnology, the new small-molecule drugs yougliptin tablets and CX3002 tablets are about to undergo phase III and phase II clinical trials respectively; the new biological class 1 drug EP-9001A injection has been submitted to the IND.
Phase I clinical trials will be launched soon
.
Yuandong Bio is focusing on researching Class 1 new drugs.
Source: The company announced that Eulogliptin tablets are DPP-4 inhibitors.
It is the first oral long-acting hypoglycemic agent for type 2 diabetes declared in China.
It is planned to be administered once a week.
It is mainly excreted through the intestinal tract and is more suitable for patients with diabetic nephropathy
.
At present, there is no oral hypoglycemic drug that is administered once a week in the market
.
CX3002 tablets are a new type of oral factor Xa inhibitor, which is used to prevent the formation of acute deep vein thrombosis.
It is safer than traditional oral anticoagulants and has a lower risk of bleeding
.
Among the same target drugs, Eliquis (apixaban) and Xarelto (rivaroxaban) have global sales of 9.
168 billion U.
S.
dollars and 7.
498 billion U.
S.
dollars respectively in 2020
.
Among the three new biological class 1 drugs being developed by Yuandong Biological, the narcotic analgesic EP-9001A injection is about to start clinical trials.
The indication is bone metastasis cancer pain, and its mechanism of action can be complementary to opioids or non-steroids.
.
According to data from Meinenet, in 2020, the sales of terminal opioid painkillers in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 12 billion yuan
.
It is worth mentioning that the field of anesthesia and analgesia is a product pipeline that Yuandong Biotechnology focuses on.
At present, the company has listed 9 products in anesthesia and analgesia and related fields, and more than 20 are under research, including 5 new drugs and 9 controlled special drugs.
One, committed to becoming a leader in the field of anesthesia and analgesia
.
Data source: Mi Nei.
com database, company announcement
With the continuous growth of sales of its main products and the contribution of new increments from centralized procurement and bidding, the company achieved a net profit of 117 million yuan, a year-on-year increase of 36.
32%
.
The company's follow-up performance is expected to continue to receive "assistances" in centralized procurement: 3 varieties won the bid for the fifth batch of centralized procurement, and two "barefoot" varieties are expected to be included in the sixth batch of centralized procurement
.
The company continues to accelerate its innovation and transformation.
Among the more than 10 class 1 innovative drugs under development, the small molecule new drugs yougliptin tablets and CX3002 tablets will start phase III and phase II clinical trials respectively; the new biological class 1 drug EP-9001A injection will soon Carry out I clinical trials
.
Net profit soared 36.
32% ! Yuandong
Biotech’s net profit of “assisted” by the new bid-winning products (unit: 100 million yuan) Recently, Yuandong Biotech, a pharmaceutical company listed on the Science and Technology Innovation Board, released its 2021 semi-annual report.
The company achieved operating income of 499 million yuan in the first half of the year, a year-on-year increase of 14.
65 %; Achieved a net profit of 117 million yuan, a year-on-year increase of 36.
32%
.
For revenue, net profit double reason for the growth, bio-Yuan Dong, said the company's main products are chemicals sector ibandronate injection and other sales continued to grow, etoricoxib film the third installment of the successful National Drug centralized purchasing contribution Due to the new increment
.
It is worth noting that this is not the first time that Yuandong Biotech's net profit has benefited from the growth of collectively sourced varieties
.
On January 17, 2020, the second batch of centralized procurement was opened.
Yuandong Biological's bisoprolol fumarate tablets won the first place.
The increase in sales has become one of the factors for the company's 2020 net profit growth of 64.
04%
.
The follow-up performance of Yuandong Biology is also expected to continue to receive "assistances" from collectively sourced varieties
.
In the fifth batch of centralized procurement, which opened on June 23, the three shortlisted varieties of Yuandong Biotechnology won the first bid.
Among them, glycopyrrolate injection and dabigatran etexilate capsules were released in November 2020.
It was approved for production in April and April 2021, and the market is waiting to be developed; although Fasudil Hydrochloride Injection has been on the market for many years, its market share is relatively low
.
Winning the bids for the three varieties of national procurement will help expand sales and quickly open up the domestic market
.
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
15 products have been over-evaluated, and 12 new products have
passed/deemedly passed the consistency evaluation.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Yuandong Bio has 15 varieties (28 product regulations) passed/deemed to have passed the consistency evaluation, of which 4 varieties have been evaluated for the first time, and ibandronate sodium injection has temporarily been evaluated exclusively
.
It is worth noting that Paricalcitol injection, propofol tenofovir fumarate tablets, coffee citrate/phenanthrene/injection, memantine hydrochloride sustained-release capsules, ibandronate sodium injection, etc.
Five varieties have not yet been included in the collection
.
The sixth batch of centralized procurement is expected to be launched at the end of this year.
Three types of over-evaluated companies including Memantine Hydrochloride Sustained Release Capsules, Citrate Coffee/Ephine/Yin Injection, Propofol Fumarate Tenofovir Tablets, etc.
have reached 4 Home, 6, and 12 are expected to be included in the next batch of centralized procurement
.
Among them, Yuandong Bio's memantine hydrochloride sustained-release capsules and propofol tenofovir fumarate tablets have just been approved soon.
If the bid is won, it is expected to bring new increments
.
According to data from Mi Nei.
com, there are currently 11 new registered classification varieties (15 acceptance numbers) currently under review by Yuandong Biotechnology, which will be deemed to have passed the consistency evaluation after approval for production
.
Among them, three varieties of bripiprazole tablets, sugammadex sodium injection, and ibuprofen tromethamine injection have not been approved for generic drugs in the domestic market, and ibuprofen tromethamine injection has been approved by Yuanyuan Dong Biotech’s exclusive report for production, is expected to win the first imitation
.
Yuandong Biologics is reviewing the new registration classification of generic drugs.
Source: Meinenet MED2.
0 China Drug Evaluation Database 9 major Class 1 new drugs are eye-
catching , aiming at the field of narcotic and analgesia Yuandong
Biologics R&D expenses (unit: 100 million yuan) In recent years, Yuandong Biology continues to maintain a high R&D investment, has a rich layout in research pipelines, and builds a benign product iteration capability to ensure sustainable development
.
In the first half of 2021, Yuandong Biotechnology's research and development expenses were RMB 94,290,500, a year-on-year increase of 43.
16%
.
Currently, Yuandong Biology has more than 50 research projects, and innovative drug projects account for 20%.
It focuses on key areas to coordinate the deployment of small molecule entities, biological drugs and high-end generic drug product groups, covering diabetes, cardiovascular, anesthesia, analgesia, and anti-inflammatory drugs.
Oncology field
.
Among the more than 10 Class 1 innovative drugs being developed by Yuandong Biotechnology, the new small-molecule drugs yougliptin tablets and CX3002 tablets are about to undergo phase III and phase II clinical trials respectively; the new biological class 1 drug EP-9001A injection has been submitted to the IND.
Phase I clinical trials will be launched soon
.
Yuandong Bio is focusing on researching Class 1 new drugs.
Source: The company announced that Eulogliptin tablets are DPP-4 inhibitors.
It is the first oral long-acting hypoglycemic agent for type 2 diabetes declared in China.
It is planned to be administered once a week.
It is mainly excreted through the intestinal tract and is more suitable for patients with diabetic nephropathy
.
At present, there is no oral hypoglycemic drug that is administered once a week in the market
.
CX3002 tablets are a new type of oral factor Xa inhibitor, which is used to prevent the formation of acute deep vein thrombosis.
It is safer than traditional oral anticoagulants and has a lower risk of bleeding
.
Among the same target drugs, Eliquis (apixaban) and Xarelto (rivaroxaban) have global sales of 9.
168 billion U.
S.
dollars and 7.
498 billion U.
S.
dollars respectively in 2020
.
Among the three new biological class 1 drugs being developed by Yuandong Biological, the narcotic analgesic EP-9001A injection is about to start clinical trials.
The indication is bone metastasis cancer pain, and its mechanism of action can be complementary to opioids or non-steroids.
.
According to data from Meinenet, in 2020, the sales of terminal opioid painkillers in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 12 billion yuan
.
It is worth mentioning that the field of anesthesia and analgesia is a product pipeline that Yuandong Biotechnology focuses on.
At present, the company has listed 9 products in anesthesia and analgesia and related fields, and more than 20 are under research, including 5 new drugs and 9 controlled special drugs.
One, committed to becoming a leader in the field of anesthesia and analgesia
.
Data source: Mi Nei.
com database, company announcement
